Table 3

Summary of recent large prospective studies of herpes simplex virus transmission

Brown et al31Langenberg et al32Mertz et al33Wald et al34
HSV, herpes simplex virus
Year of publication1997199919922001
SettingTwo antenatal clinics (University Hospital Seattle and Madigan Army Hospital, Tacoma)Two multicentre randomised controlled trials of an ineffective HSV-2 vaccineTwo university research clinicsMulticentre randomised controlled trials of an ineffective HSV-2 vaccine
Participants7046 pregnant women at risk for HSV acquisition2393 sexually active adults at high risk of HSV-2 acquisition144 heterosexual couples discordant for genital HSV infection (97% had HSV-2)528 monogamous couples discordant for HSV-2 infection
Duration of follow upDuration of pregnancy18 monthsMedian 334 days18 months
Outcome measure(s)Type specific seroconversionCulture proven HSV infection or type specific seroconversion in susceptible partnerCulture proven HSV infection or type specific seroconversion in susceptible partnerAcquisition of HSV-2 infection by susceptible partner
Transmisson rateHSV-1 : 2.3 % (± SE 0.4)HSV-1 : 1.0/100 person years16.9%9.7%
(Male to female)HSV-2 : 1.6% (± SE 0.4)HSV-2 : 6.8/100 person years
Transmisson rateHSV-1 : 1.9/100 person years3.8%1.9%
(Female to male)HSV-2 : 4.4/100 person years
Effect of pre-existing HSV-1 antibodies on risk of acquisitionNo protective effect demonstratedNo protective effect demonstratedProtective for female susceptible partners onlyNo protective effect demonstrated
Effect of pre-existing HSV-1 antibodies on risk of transmissionNo effect demonstratedIncreased risk of transmission in HSV-1 and HSV-2 coinfected source partners
Effect of condoms on risk of transmissionNo effect demonstratedUse in >25% of sex acts protective for female susceptible partners
Other determinants of transmissionAge, frequency of sexual activity, duration of relationship